Exelixis (NASDAQ:EXEL) Rating Lowered to “Equal Weight” at Wells Fargo & Company
Exelixis (NASDAQ:EXEL – Get Free Report) was downgraded by equities researchers at Wells Fargo & Company from an “overweight” rating to an “equal weight” rating in a research report issued to clients and investors on Monday, Marketbeat reports. They currently have a $36.00 price target on the biotechnology company’s stock. Wells Fargo & Company‘s price […]
Exelixis (NASDAQ:EXEL – Get Free Report) was downgraded by equities researchers at Wells Fargo & Company from an “overweight” rating to an “equal weight” rating in a research report issued to clients and investors on Monday, Marketbeat reports. They currently have a $36.00 price target on the biotechnology company’s stock. Wells Fargo & Company‘s price […]
